1. Home
  2. INKT vs IRD Comparison

INKT vs IRD Comparison

Compare INKT & IRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INKT
  • IRD
  • Stock Information
  • Founded
  • INKT 2017
  • IRD 2018
  • Country
  • INKT United States
  • IRD United States
  • Employees
  • INKT N/A
  • IRD N/A
  • Industry
  • INKT Medicinal Chemicals and Botanical Products
  • IRD
  • Sector
  • INKT Health Care
  • IRD
  • Exchange
  • INKT Nasdaq
  • IRD NYSE
  • Market Cap
  • INKT 36.7M
  • IRD 36.0M
  • IPO Year
  • INKT 2021
  • IRD N/A
  • Fundamental
  • Price
  • INKT $9.50
  • IRD $1.13
  • Analyst Decision
  • INKT Strong Buy
  • IRD Strong Buy
  • Analyst Count
  • INKT 2
  • IRD 1
  • Target Price
  • INKT $6.50
  • IRD $8.00
  • AVG Volume (30 Days)
  • INKT 72.8K
  • IRD 150.5K
  • Earning Date
  • INKT 03-20-2025
  • IRD 02-24-2025
  • Dividend Yield
  • INKT N/A
  • IRD N/A
  • EPS Growth
  • INKT N/A
  • IRD N/A
  • EPS
  • INKT N/A
  • IRD N/A
  • Revenue
  • INKT N/A
  • IRD $8,381,000.00
  • Revenue This Year
  • INKT N/A
  • IRD N/A
  • Revenue Next Year
  • INKT N/A
  • IRD $29.37
  • P/E Ratio
  • INKT N/A
  • IRD N/A
  • Revenue Growth
  • INKT N/A
  • IRD N/A
  • 52 Week Low
  • INKT $4.56
  • IRD $0.81
  • 52 Week High
  • INKT $19.00
  • IRD $2.71
  • Technical
  • Relative Strength Index (RSI)
  • INKT 52.27
  • IRD N/A
  • Support Level
  • INKT $8.85
  • IRD N/A
  • Resistance Level
  • INKT $13.79
  • IRD N/A
  • Average True Range (ATR)
  • INKT 1.93
  • IRD 0.00
  • MACD
  • INKT -0.07
  • IRD 0.00
  • Stochastic Oscillator
  • INKT 53.50
  • IRD 0.00

About INKT MiNK Therapeutics Inc.

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.

About IRD OPUS GENETICS INC

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

Share on Social Networks: